Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Dermatol ; 50(5): 710-714, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-36514908

RESUMEN

Vitiligo is a common depigmenting skin disease that is often difficult to treat. Even if repigmentation is achieved by treatment, recurrence in the same lesion is often found within a year after stopping treatment. As a background of these issues, a subset of CD8+ T cells that recognize melanocyte-specific antigens or CD49a+ tissue-resident memory T cells that reside in the vitiligo lesion are thought to be involved. We investigated the MHC class I-restricted tyrosinase pentamer-positive CD8+ skin T cells in a progressive generalized vitiligo patient with HLA-A*02:01 who showed resistance to intravenous methylprednisolone pulse therapy. We found that HLA-A*02:01-restricted tyrosinase pentamer-positive CD8+ T cells remained in the lesions after the treatment and expressed IFN-γ and granzyme B. Interestingly, the expression of these cytokines in the pentamer-negative CD8+ T cells was decreased after intravenous methylprednisolone pulse therapy. These findings suggest that, in vitiligo patients, melanocyte-specific CD49a+ CD8+ T cells are in a potent activation state that is uncontrolled despite systemic immunosuppressive treatment, which may contribute to treatment resistance and local recurrence.


Asunto(s)
Hipopigmentación , Vitíligo , Humanos , Vitíligo/patología , Linfocitos T CD8-positivos , Integrina alfa1 , Monofenol Monooxigenasa , Melanocitos/patología , Antígenos HLA-A , Metilprednisolona/farmacología , Metilprednisolona/uso terapéutico , Esteroides
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA